| scholarly article | Q13442814 |
| P2093 | author name string | Antonia J Cronin | |
| Kieron S Leslie | |||
| Timur A Galperin | |||
| P2860 | cites work | Long-term outcomes in patients with calciphylaxis from hyperparathyroidism | Q82083954 |
| Heart of stone | Q82786741 | ||
| Fulminant pulmonary calciphylaxis and metastatic calcification causing acute respiratory failure in a uremic patient | Q82971648 | ||
| Acquired perforating dermatosis successfully treated with photodynamic therapy | Q83161980 | ||
| Nephrogenic systemic fibrosis associated with stromal and vascular calcification, report of two cases | Q83331054 | ||
| Treatment of acquired perforating dermatosis with cantharidin | Q83479252 | ||
| Bullous skin lesions in a patient undergoing chronic hemodialysis | Q83889241 | ||
| Successful treatment of calcific uraemic arteriolopathy with bisphosphonates | Q84148277 | ||
| Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients | Q84456276 | ||
| Secondary hyperparathyroidism: pathophysiology and treatment | Q84521431 | ||
| Acquired perforating dermatoses in patients with diabetic kidney disease on hemodialysis | Q84565539 | ||
| The porphyrias: advances in diagnosis and treatment | Q84569566 | ||
| Net-like pattern of calcification on plain soft-tissue radiographs in patients with calciphylaxis | Q84649586 | ||
| Alefacept therapy for nephrogenic systemic fibrosis: a case series | Q84699088 | ||
| Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging | Q22065113 | ||
| New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma | Q24615751 | ||
| Evolution of treatment strategies for calciphylaxis | Q27012859 | ||
| Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B | Q28265362 | ||
| Calciphylaxis: natural history, risk factor analysis, and outcome | Q28276841 | ||
| Acquired perforating dermatosis in patients with chronic renal failure and diabetes mellitus | Q33654779 | ||
| Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches | Q34185823 | ||
| Treatment of cutaneous calciphylaxis with sodium thiosulfate: two case reports and a review of the literature | Q34207447 | ||
| Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study | Q34420464 | ||
| Prevention of irritant contact dermatitis | Q34505116 | ||
| Acquired perforating dermatosis: clinicopathological features in twenty-two cases | Q34546899 | ||
| Randomized, double-blind study with glycerol and paraffin in uremic xerosis. | Q34751820 | ||
| Circulating fibrocytes: collagen-secreting cells of the peripheral blood | Q35686362 | ||
| Acquired disorders of elastic tissue: part I. Increased elastic tissue and solar elastotic syndromes | Q35831182 | ||
| Effect of sertraline on uremic pruritus improvement in ESRD patients | Q36220860 | ||
| Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity | Q36478196 | ||
| Platelet dysfunction and end-stage renal disease | Q36558730 | ||
| Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature | Q36808088 | ||
| An update on pruritus associated with CKD. | Q36859903 | ||
| Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting | Q37121250 | ||
| Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature | Q37218829 | ||
| Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis | Q37219177 | ||
| Cutaneous manifestations of chronic kidney disease | Q37221730 | ||
| Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue | Q37318510 | ||
| Nephrogenic systemic fibrosis: histology and gadolinium detection | Q37595018 | ||
| Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options | Q37616516 | ||
| Innovative management of pruritus. | Q37761504 | ||
| Acquired reactive perforating collagenosis: current status | Q37772557 | ||
| Nephrogenic Systemic Fibrosis: A Mysterious Disease in Patients with Renal Failure--Role of Gadolinium-Based Contrast Media in Causation and the Beneficial Effect of Intravenous Sodium Thiosulfate | Q61795165 | ||
| Quality of Life in Patients with Uraemic Xerosis and Pruritus | Q62661912 | ||
| Reactive perforating collagenosis of renal failure/diabetes responsive to topical retinoic acid | Q69649494 | ||
| Oral activated charcoal in patients with uremic pruritus | Q71759733 | ||
| Sweat secretion, stratum corneum hydration, small nerve function and pruritus in patients with advanced chronic renal failure | Q71785279 | ||
| Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial | Q72742589 | ||
| Plasma concentrations of alpha-melanocyte-stimulating hormone are elevated in patients on chronic haemodialysis | Q74053495 | ||
| Successful treatment of acquired reactive perforating collagenosis with doxycycline | Q78512045 | ||
| Two cases of acquired perforating dermatosis treated with doxycycline therapy | Q79446805 | ||
| Hemodialysis-related pruritus and associated cutaneous manifestations | Q79780022 | ||
| Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus | Q79782064 | ||
| Cinacalcet for the treatment of calciphylaxis | Q79798731 | ||
| Treatment of acquired perforating dermatosis with narrowband ultraviolet B | Q80111675 | ||
| Uremic pruritus | Q80147721 | ||
| Generalized pruritus treated with narrowband UVB | Q80176449 | ||
| Uraemic xerosis | Q80490157 | ||
| Gabapentin: a promising drug for the treatment of uremic pruritus | Q80750289 | ||
| Characteristics of acquired reactive perforating collagenosis | Q80863113 | ||
| Treatment of acquired perforating dermatosis with narrowband ultraviolet B | Q81363849 | ||
| Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation | Q81802161 | ||
| Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study | Q81867634 | ||
| Calciphylaxis | Q81969638 | ||
| Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature | Q37809682 | ||
| Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat? | Q37835580 | ||
| Iron and vascular calcification. Is there a link? | Q37843115 | ||
| Calcinosis cutis: part I. Diagnostic pathway | Q37890579 | ||
| Calciphylaxis: a systematic review of existing and emerging therapies | Q37912762 | ||
| Multi-intervention management of calciphylaxis: a report of 7 cases | Q37923005 | ||
| Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases | Q37957344 | ||
| Diagnosis of common dermopathies in dialysis patients: a review and update | Q38027184 | ||
| Retrospective analysis of tissue plasminogen activator as an adjuvant treatment for calciphylaxis. | Q38074532 | ||
| Report: Cutaneous disorders in uremic patients on hemodialysis: an Egyptian case‐controlled study | Q38883318 | ||
| Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). | Q39346154 | ||
| Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase | Q39905148 | ||
| Acquired perforating dermatosis in a British dialysis population | Q41285276 | ||
| The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients | Q42849981 | ||
| Topical capsaicin therapy for uremic pruritus in patients on hemodialysis. | Q43092981 | ||
| Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study. | Q43223186 | ||
| An epidemiology study of patients with uremic pruritus | Q43857445 | ||
| Reactive perforating collagenosis: a condition that may be underdiagnosed | Q43923130 | ||
| Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study | Q44030301 | ||
| Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies | Q44350825 | ||
| A case-control study of calciphylaxis in Japanese end-stage renal disease patients | Q44361391 | ||
| Determinants of survival in patients with calciphylaxis: a multivariate analysis | Q44620266 | ||
| Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial | Q45170301 | ||
| Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients | Q45263782 | ||
| Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial. | Q45761415 | ||
| Gabapentin and uremic pruritus in hemodialysis patients | Q46124053 | ||
| A giant variant of acquired reactive perforating collagenosis associated with hydronephrosis: successful treatment with allopurinol | Q46129971 | ||
| A randomized controlled trial of high-permeability haemodialysis against conventional haemodialysis in the treatment of uraemic pruritus | Q46142927 | ||
| Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate | Q46235741 | ||
| Imatinib in the treatment of nephrogenic systemic fibrosis | Q46243458 | ||
| Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis | Q46260416 | ||
| K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease | Q46286369 | ||
| A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients | Q46343813 | ||
| Imatinib mesylate treatment of nephrogenic systemic fibrosis | Q46453956 | ||
| Nail changes in chronic renal failure patients under haemodialysis | Q46485644 | ||
| Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates | Q46894346 | ||
| Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'. | Q46970567 | ||
| Acquired reactive perforating collagenosis: four patients with a giant variant treated with allopurinol | Q46990135 | ||
| Use of pregabalin in the management of chronic uremic pruritus | Q47359210 | ||
| Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients | Q48229402 | ||
| Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial | Q48298203 | ||
| Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study | Q48381465 | ||
| Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients | Q48502316 | ||
| Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark. | Q50554000 | ||
| Cutaneous calcification in patients with end-stage renal disease: a regulated process associated with in situ osteopontin expression. | Q51795352 | ||
| The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. | Q53651902 | ||
| Predictors of acquired perforating dermatosis in uremic patients on hemodialysis: a case-control study. | Q55504665 | ||
| Calciphylaxis is usually non-ulcerating: Risk factors, outcome and therapy | Q59391874 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 201-218 | |
| P577 | publication date | 2013-10-10 | |
| P1433 | published in | Clinical Journal of the American Society of Nephrology | Q15757929 |
| P1476 | title | Cutaneous manifestations of ESRD. | |
| P478 | volume | 9 |
| Q42246906 | Acquired perforating dermatosis in a diabetic patient on hemodialysis |
| Q39048008 | Bullous Dermatosis in an End-Stage Renal Disease Patient: A Case Report and Literature Review. |
| Q93234087 | Chronic dialysis in patients with end-stage renal disease: Relevance to kidney xenotransplantation |
| Q48271594 | Clinical interpretation of the Uremic Pruritus in Dialysis Patients (UP-Dial) scale: a novel instrument for the assessment of uremic pruritus |
| Q47841918 | Cutaneuos findings in patients with predialysis chronic kidney disease. |
| Q37205352 | Edema, Hyperpigmentation, Induration: 3 Skin Signs Heralding Danger in Patients on Maintenance Hemodialysis |
| Q90237217 | Furosemide-induced pseudoporphyria in a patient with chronic kidney disease: case report |
| Q90595467 | Risk of Skin Diseases in Maintenance Hemodialysis |
| Q92921841 | Skin Cutibacterium acnes Mediates Fermentation to Suppress the Calcium Phosphate-Induced Itching: A Butyric Acid Derivative with Potential for Uremic Pruritus |
| Q37073960 | Skin disorders in peritoneal dialysis patients: An underdiagnosed subject |
| Q35831040 | Wound Healing in Patients With Impaired Kidney Function |
Search more.